Nyxoah (NASDAQ:NYXH) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Nyxoah reported quarterly earnings of ($0.63) EPS, missing analysts' estimates by ($0.03).
• The company has a negative return on equity of 63.37% and a negative net margin of 1,571.39%.
• Stifel Nicolaus reduced their target price on Nyxoah shares from $15.00 to $14.00 while maintaining a "buy" rating.

Nyxoah (NASDAQ:NYXH - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01), Zacks reports. Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%.The company had revenue of $1.58 million during the quarter, compared to analysts' expectations of $1.33 million.

Nyxoah Stock Down 1.1%

Shares of NASDAQ NYXH traded down $0.07 on Thursday, reaching $6.28. 66,400 shares of the company's stock traded hands, compared to its average volume of 106,753. The business's 50 day simple moving average is $7.49 and its two-hundred day simple moving average is $7.95. The company has a market cap of $213.90 million, a price-to-earnings ratio of -2.73 and a beta of 1.61. Nyxoah has a 12 month low of $5.55 and a 12 month high of $11.87. The company has a quick ratio of 3.35, a current ratio of 2.63 and a debt-to-equity ratio of 0.29.

Institutional Trading of Nyxoah

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company's stock worth $59,000 after acquiring an additional 3,303 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Nyxoah during the second quarter valued at $70,000. Finally, Shay Capital LLC purchased a new stake in shares of Nyxoah during the second quarter valued at $374,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.